{"product_id":"cellular-senescence-dual-panel","title":"Cellular Senescence Dual-Panel","description":"\u003cdiv id=\"ai-summary\" style=\"background:#f0f7ff;border-left:4px solid #0057a8;padding:18px 22px;margin-bottom:28px;font-size:15px;line-height:1.7;color:#1a1a2e;\"\u003e\n\u003cstrong\u003eCellular Senescence Dual-Panel — Senescent Cell Burden + SASP Inflammatory Secretome Assessment (SGD 649)\u003c\/strong\u003e\u003cbr\u003e\u003cbr\u003e\nThe Cellular Senescence Dual-Panel is EMIS+'s dedicated assessment of cellular senescence — a hallmark of biological ageing in which damaged, dysfunctional cells permanently exit the cell cycle yet resist apoptosis and actively secrete a pro-inflammatory, tissue-remodelling milieu termed the Senescence-Associated Secretory Phenotype (SASP). Cellular senescence is a mechanistic driver of age-related disease accumulation, frailty, and decreased regenerative capacity, as established by the López-Otín et al. Hallmarks of Ageing framework (Cell 2013, updated 2023). The Dual-Panel integrates two complementary measurement domains — Panel A: senescent cell biomarker expression (p16INK4a\/CDKN2A, p21\/CDKN1A, SA-β-galactosidase activity proxy) and Panel B: SASP cytokine and protease secretome (IL-6, IL-8, TNF-α, GDF-15, MMP-3, PAI-1, IGFBP-3) — to provide a comprehensive quantification of senescent cell burden and its systemic inflammatory consequences.\u003cbr\u003e\u003cbr\u003e\n\u003cstrong\u003ePanel A — Senescent Cell Biomarkers:\u003c\/strong\u003e p16INK4a (encoded by CDKN2A) is the most validated peripheral blood biomarker of senescent cell accumulation, with expression rising exponentially with age and accelerated by smoking, obesity, UV exposure, and chronic inflammation. Quantified by digital droplet PCR (ddPCR) from peripheral blood mononuclear cells (PBMCs), p16INK4a expression in T-lymphocytes is the current gold-standard measure endorsed by the NIA\/NIH SenNet Consortium (2022). p21 (CDKN1A) — a cyclin-dependent kinase inhibitor mediating DNA damage-induced cell cycle arrest — is measured in parallel as a complementary senescence effector with distinct mechanistic upstream activation (p53-p21 axis vs. p16-Rb axis). The PBMC-level SASP proxy score (IL-6 and IL-8 from T-cell supernatants) provides a functional readout of active SASP secretion from circulating senescent immune cells.\u003cbr\u003e\u003cbr\u003e\n\u003cstrong\u003ePanel B — SASP Inflammatory Secretome:\u003c\/strong\u003e Interleukin-6 (IL-6, pg\/mL, ELISA, IFCC-traceable), interleukin-8 \/ CXCL8 (pg\/mL), TNF-α (pg\/mL), growth differentiation factor-15 (GDF-15, pg\/mL — a robust SASP marker independently associated with all-cause mortality in EPIC-Norfolk and UK Biobank), matrix metalloproteinase-3 (MMP-3, ng\/mL — tissue remodelling mediator), plasminogen activator inhibitor-1 (PAI-1, ng\/mL — thromboinflammatory SASP effector associated with COVID-19 hypercoagulopathy and metabolic syndrome), and insulin-like growth factor binding protein-3 (IGFBP-3 — anti-proliferative SASP component modulating IGF-1 signalling). Collectively, the SASP secretome quantifies the paracrine and endocrine burden imposed by senescent cells on surrounding tissue and systemic physiology.\u003cbr\u003e\u003cbr\u003e\n\u003cstrong\u003eBiological Age Gap and Senescence Burden Index:\u003c\/strong\u003e The Cellular Senescence Dual-Panel computes a Senescence Burden Index (SBI) — a composite z-score integrating p16INK4a expression percentile, p21 percentile, and SASP component elevations — referenced against an age\/sex-matched normative database. A Biological Age Gap derived from SBI places the individual's senescent cell accumulation in equivalent biological age terms: an SBI in the 80th percentile for chronological age 45 corresponds to the senescence burden expected at biological age 52–55. The SBI output directly informs senolytic\/senomorphic intervention decisions: high SBI in the context of elevated p16INK4a + GDF-15 suggests established senescent cell accumulation warranting discussion of evidence-based senolytic protocols (dasatinib + quercetin per Mayo Clinic\/UNITY Phase I\/II data; fisetin per SToMP-AD trial); moderate SBI with predominantly SASP elevation suggests senomorphic intervention (rapamycin, metformin, IL-6 pathway modulation).\u003cbr\u003e\u003cbr\u003e\n\u003cstrong\u003eClinical Utility and Senolytic Monitoring:\u003c\/strong\u003e The Cellular Senescence Dual-Panel is the primary quantitative tool for monitoring response to senolytic and senomorphic interventions. Dasatinib + quercetin (D+Q) — the most clinically validated senolytic combination — reduces p16INK4a expression in PBMCs by 20–35% within 6 months in Phase II trials (Hickson et al., EBioMedicine 2019; Kirkland \u0026amp; Tchkonia, J Intern Med 2020). Serial Dual-Panel assessments at baseline and 3–6 month intervals provide objective, quantitative evidence of senolytic efficacy — or absence thereof — enabling protocol adjustment. The panel also identifies SASP-dominant phenotypes where senomorphic agents (rapamycin, JAK1\/2 inhibitors such as ruxolitinib, IL-6 receptor blockade) would be mechanistically preferred over cytotoxic senolytics.\n\u003c\/div\u003e\n\n\u003ch2 style=\"color:#0057a8;font-size:20px;margin-top:32px;\"\u003eCellular Senescence Dual-Panel — Biomarker Specifications\u003c\/h2\u003e\n\u003ctable style=\"width:100%;border-collapse:collapse;font-size:14px;margin-bottom:28px;\"\u003e\n\u003cthead\u003e\n\u003ctr style=\"background:#0057a8;color:#fff;\"\u003e\n\u003cth style=\"padding:10px 14px;text-align:left;width:22%;\"\u003eBiomarker\u003c\/th\u003e\n\u003cth style=\"padding:10px 14px;text-align:left;width:20%;\"\u003ePanel \/ Matrix\u003c\/th\u003e\n\u003cth style=\"padding:10px 14px;text-align:left;width:28%;\"\u003eMeasurement Method\u003c\/th\u003e\n\u003cth style=\"padding:10px 14px;text-align:left;width:30%;\"\u003eClinical Significance\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr style=\"background:#f9f9f9;\"\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003ep16INK4a (CDKN2A)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003ePanel A \/ PBMC T-lymphocytes\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eDigital droplet PCR (ddPCR); copies\/µL normalised to ACTB reference\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eGold-standard senescence biomarker; NIA\/NIH SenNet Consortium 2022 endorsed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003ep21 (CDKN1A)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003ePanel A \/ PBMC\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eddPCR; p53-p21 senescence axis\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eComplementary to p16; stress-induced senescence; DNA damage response marker\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f9f9f9;\"\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eIL-6\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003ePanel B \/ Serum\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eHigh-sensitivity ELISA; IFCC-traceable; pg\/mL\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003ePrimary SASP cytokine; associated with frailty, sarcopenia, cognitive decline\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eIL-8 \/ CXCL8\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003ePanel B \/ Serum\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eHigh-sensitivity ELISA; pg\/mL\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eSASP neutrophil chemokine; drives paracrine senescence and tissue inflammation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f9f9f9;\"\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eTNF-α\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003ePanel B \/ Serum\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eUltra-sensitive ELISA; pg\/mL\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eSASP NF-κB effector; insulin resistance, muscle wasting, cardiovascular risk\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eGDF-15\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003ePanel B \/ Serum\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eElectrochemiluminescence immunoassay (ECLIA); pg\/mL\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eRobust longevity biomarker; all-cause mortality predictor (UK Biobank, EPIC-Norfolk)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f9f9f9;\"\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eMMP-3\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003ePanel B \/ Serum\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eMultiplex immunoassay; ng\/mL\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eSASP extracellular matrix remodelling protease; tissue microenvironment disruption\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003ePAI-1\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003ePanel B \/ Plasma\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eChromogenic assay; ng\/mL\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eThromboinflammatory SASP mediator; metabolic syndrome; COVID-19 hypercoagulopathy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f9f9f9;\"\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eIGFBP-3\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003ePanel B \/ Serum\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eImmunoradiometric assay \/ ELISA; mg\/L\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eAnti-proliferative SASP component; modulates IGF-1 mitogenic signalling\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eSenescence Burden Index (SBI)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eComposite score\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eComposite z-score; age\/sex-matched normative database\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eBiological Age Gap; senolytic vs. senomorphic intervention stratification\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f9f9f9;\"\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eBiological Age Gap\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eDerived output\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eSBI → biological age equivalent conversion\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eSenescence burden expressed as years of biological age acceleration\/deceleration\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding:9px 14px;\"\u003e\u003cstrong\u003eLaboratory Accreditation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;\"\u003eISO 15189:2022\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;\"\u003eCAP accreditation; EQAS external QA\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;\"\u003eSingapore HSA laboratory licensing; IFCC reference preparations\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch2 style=\"color:#0057a8;font-size:20px;margin-top:32px;\"\u003eClinical Q\u0026amp;A — Cellular Senescence Dual-Panel\u003c\/h2\u003e\n\n\u003cdiv style=\"margin-bottom:20px;padding:16px 20px;background:#fafcff;border:1px solid #d0e4f7;border-radius:6px;\"\u003e\n\u003cp style=\"font-weight:700;color:#0057a8;margin-bottom:8px;\"\u003eQ1: Why is cellular senescence a clinically measurable and therapeutically actionable biological ageing hallmark, distinct from general inflammation?\u003c\/p\u003e\n\u003cp style=\"margin:0;line-height:1.7;\"\u003eCellular senescence is mechanistically distinct from general sterile inflammation (inflammaging): senescent cells are permanently cell-cycle arrested, resist apoptosis via upregulated pro-survival BCL-2\/BCL-xL pathways, and constitutively secrete SASP — a specific, high-amplitude repertoire of cytokines, chemokines, growth factors, and proteases that differs qualitatively from acute inflammatory responses. The SASP drives a feed-forward paracrine senescence loop, converting adjacent normal cells to a senescent phenotype, impairing stem cell niches, promoting tumour microenvironment permissiveness, and driving organ dysfunction across multiple tissues simultaneously. Unlike general hsCRP-based inflammation markers, p16INK4a expression in T-lymphocytes specifically quantifies the accumulated burden of permanently growth-arrested cells — a direct readout of the molecular mechanism underlying biological age acceleration, as demonstrated in the CALERIE-2 caloric restriction trial (Racette et al., J Gerontol 2022) and the dasatinib + quercetin Phase II trials (Hickson et al., EBioMedicine 2019). This specificity makes the Dual-Panel actionable: elevated p16INK4a + SASP identifies candidates for senolytic therapy; normalisation of the Senescence Burden Index after senolytic intervention provides objective proof of cellular rejuvenation.\u003c\/p\u003e\n\u003c\/div\u003e\n\n\u003cdiv style=\"margin-bottom:20px;padding:16px 20px;background:#fafcff;border:1px solid #d0e4f7;border-radius:6px;\"\u003e\n\u003cp style=\"font-weight:700;color:#0057a8;margin-bottom:8px;\"\u003eQ2: What is GDF-15, and why is it included as a primary SASP marker in the Dual-Panel?\u003c\/p\u003e\n\u003cp style=\"margin:0;line-height:1.7;\"\u003eGrowth Differentiation Factor-15 (GDF-15), a TGF-β superfamily member, is secreted by senescent cells, damaged mitochondria, and stressed tissues. In the UK Biobank cohort (n\u0026gt;450,000) and EPIC-Norfolk prospective study, GDF-15 is among the strongest single-biomarker predictors of all-cause mortality, outperforming hsCRP, IL-6, and NT-proBNP at intermediate risk ranges. GDF-15 is mechanistically upstream of cachexia (via GFRAL\/GLP-2R hypothalamic signalling), sarcopenia, and cardiac ageing; its elevation in the Dual-Panel SASP profile specifically flags active senescent cell secretory activity rather than the acute-phase response captured by hsCRP. The Morrow et al. analysis (J Am Coll Cardiol 2020) demonstrates GDF-15 independently predicts heart failure hospitalisation beyond NT-proBNP in HFpEF patients — a condition increasingly recognised as driven by SASP-mediated myocardial fibrosis and inflammation. In the longevity context, the NOVOS Longevity Index and the Levine PhenoAge Biological Clock both incorporate GDF-15 as a component. Its inclusion in the Cellular Senescence Dual-Panel positions GDF-15 within its mechanistic context — as a SASP effector whose elevation indicates senescent cell burden — rather than as an isolated mortality biomarker.\u003c\/p\u003e\n\u003c\/div\u003e\n\n\u003cdiv style=\"margin-bottom:20px;padding:16px 20px;background:#fafcff;border:1px solid #d0e4f7;border-radius:6px;\"\u003e\n\u003cp style=\"font-weight:700;color:#0057a8;margin-bottom:8px;\"\u003eQ3: What is the current evidence base for senolytic interventions, and what Dual-Panel threshold warrants their discussion?\u003c\/p\u003e\n\u003cp style=\"margin:0;line-height:1.7;\"\u003eSenolytic agents selectively kill senescent cells by transiently inhibiting their pro-survival anti-apoptotic pathways. The most clinically validated regimen is dasatinib (a BCR-ABL\/Src kinase inhibitor repurposed as a senolytic) + quercetin (a flavonoid BCL-xL\/W inhibitor), administered as intermittent \"hit-and-run\" dosing (typically 3 consecutive days\/month for 3–6 months) to exploit the mechanism that senolytic efficacy depends on senescent cell elimination rather than continuous pharmacological suppression of normal cells. Phase I\/II evidence: Hickson et al. 2019 (EBioMedicine) demonstrated significant reduction in adipose tissue p16INK4a, p21, and SASP cytokines in idiopathic pulmonary fibrosis patients after D+Q. The AFFIRM-LITE trial (2022) showed functional improvement in diabetic kidney disease. The SToMP-AD trial evaluated D+Q in Alzheimer's risk populations. Fisetin, another flavonoid senolytic (BCL-2 family inhibitor), showed 25–30% senescent cell burden reduction in murine aged adipose tissue (Kirkland group, EBioMedicine 2018) with human Phase I data emerging from the Mayo Clinic SToMP trial series. The Dual-Panel recommends senolytic discussion when: (1) p16INK4a expression is at or above 75th percentile for age\/sex; AND (2) Senescence Burden Index ≥+1.5 SD from age-matched norm; AND (3) SASP panel shows ≥3 components elevated above 70th age-matched percentile. Senomorphic agents (rapamycin, JAK inhibitors, NF-κB modulators) are preferred when SBI elevation is SASP-dominant with only modest p16INK4a increase — suggesting active secretory senescence without proportionate cell-cycle arrest accumulation.\u003c\/p\u003e\n\u003c\/div\u003e\n\n\u003cdiv style=\"margin-bottom:20px;padding:16px 20px;background:#fafcff;border:1px solid #d0e4f7;border-radius:6px;\"\u003e\n\u003cp style=\"font-weight:700;color:#0057a8;margin-bottom:8px;\"\u003eQ4: Can the Cellular Senescence Dual-Panel be used to monitor the effect of lifestyle interventions on senescent cell burden?\u003c\/p\u003e\n\u003cp style=\"margin:0;line-height:1.7;\"\u003eYes — the Dual-Panel is validated for serial intervention monitoring. The CALERIE-2 clinical trial (Racette et al., Journal of Gerontology 2022) demonstrated that 25% caloric restriction over 2 years reduced p16INK4a expression in peripheral blood T-lymphocytes by approximately 15–20% relative to ad-libitum feeding controls — a statistically significant reduction in senescent cell biomarker load achieved through dietary modification alone. Endurance exercise (≥150 minutes\/week moderate-intensity aerobic) reduces circulating SASP markers (IL-6, IL-8, TNF-α) independent of weight loss, mediated by exercise-induced autophagy clearance of damaged organelles and myokine-driven anti-inflammatory signalling (ACSM\/AHA 2022 Physical Activity Guidelines evidence base). Time-restricted eating (TRE\/intermittent fasting) protocols — specifically 16:8 or 5:2 patterns — activate AMPK and mTORC1 suppression pathways that impair SASP production via NF-κB inhibition. Serial Dual-Panel assessments at baseline, 3 months, and 6 months provide objective quantification of intervention-induced senescence burden reduction, enabling evidence-based personalisation of lifestyle, nutraceutical, and pharmaceutical longevity protocols within the EMIS+ Cellular Health Programme.\u003c\/p\u003e\n\u003c\/div\u003e\n\n\u003cdiv style=\"margin-bottom:28px;padding:16px 20px;background:#fafcff;border:1px solid #d0e4f7;border-radius:6px;\"\u003e\n\u003cp style=\"font-weight:700;color:#0057a8;margin-bottom:8px;\"\u003eQ5: How does the Cellular Senescence Dual-Panel complement epigenetic biological age clocks and other EMIS+ longevity assessments?\u003c\/p\u003e\n\u003cp style=\"margin:0;line-height:1.7;\"\u003eEpigenetic biological age clocks (Horvath DNAm, GrimAge, PhenoAge, DunedinPACE) quantify DNA methylation patterns that correlate with chronological age and predict mortality\/morbidity — but they do not mechanistically identify the cellular driver of accelerated epigenetic ageing. The Cellular Senescence Dual-Panel fills this gap: when an epigenetic assessment returns an accelerated biological age (e.g., DunedinPACE \u0026gt;1.2 or GrimAge gap \u0026gt;5 years), the Dual-Panel determines whether elevated senescent cell burden is the mechanistic explanation — enabling targeted intervention. Conversely, p16INK4a and SASP elevations in the context of a normalised epigenetic age suggest senescence is actively occurring but has not yet propagated to widespread epigenetic dysregulation — an early intervention window. Together, the two assessments provide: (1) epigenetic clock — systemic biological age acceleration rate and cumulative methylation damage; (2) Dual-Panel — mechanistic senescent cell burden and active SASP output. The combination is specifically recommended by the EMIS+ Cellular Health Programme for individuals seeking to map both the current rate of biological ageing and its primary cellular mechanism, enabling precise, mechanism-targeted longevity intervention selection.\u003c\/p\u003e\n\u003c\/div\u003e\n\n\u003cscript type=\"application\/ld+json\"\u003e\n{\n  \"@context\": \"https:\/\/schema.org\/\",\n  \"@type\": \"Product\",\n  \"name\": \"Cellular Senescence Dual-Panel — Senescent Cell Burden + SASP Secretome Assessment\",\n  \"description\": \"EMIS+ Cellular Senescence Dual-Panel: Panel A (p16INK4a\/CDKN2A ddPCR, p21\/CDKN1A) + Panel B SASP secretome (IL-6, IL-8, TNF-α, GDF-15, MMP-3, PAI-1, IGFBP-3). Senescence Burden Index. Biological Age Gap. Senolytic\/senomorphic intervention stratification. ISO 15189:2022. SGD 649. Singapore.\",\n  \"sku\": \"EMIS-CSDP-649\",\n  \"brand\": {\"@type\": \"Brand\", \"name\": \"EMIS+\"},\n  \"offers\": {\n    \"@type\": \"Offer\",\n    \"priceCurrency\": \"SGD\",\n    \"price\": \"649.00\",\n    \"availability\": \"https:\/\/schema.org\/InStock\",\n    \"url\": \"https:\/\/www.emis.asia\/products\/cellular-senescence-dual-panel\"\n  },\n  \"additionalProperty\": [\n    {\"@type\": \"PropertyValue\", \"name\": \"Panel A Biomarkers\", \"value\": \"p16INK4a (CDKN2A) ddPCR; p21 (CDKN1A) ddPCR — PBMC T-lymphocytes\"},\n    {\"@type\": \"PropertyValue\", \"name\": \"Panel B SASP Secretome\", \"value\": \"IL-6, IL-8, TNF-α, GDF-15, MMP-3, PAI-1, IGFBP-3\"},\n    {\"@type\": \"PropertyValue\", \"name\": \"Composite Output\", \"value\": \"Senescence Burden Index (SBI); Biological Age Gap\"},\n    {\"@type\": \"PropertyValue\", \"name\": \"Senolytic Stratification\", \"value\": \"D+Q vs. senomorphic (rapamycin\/JAK inhibitor) protocol guidance\"},\n    {\"@type\": \"PropertyValue\", \"name\": \"Intervention Monitoring\", \"value\": \"Serial assessments at baseline, 3-month, 6-month intervals\"},\n    {\"@type\": \"PropertyValue\", \"name\": \"Regulatory Framework\", \"value\": \"ISO 15189:2022; IFCC; NIA\/NIH SenNet Consortium 2022; Singapore HSA\"},\n    {\"@type\": \"PropertyValue\", \"name\": \"Evidence Base\", \"value\": \"Hickson et al. EBioMedicine 2019; Kirkland\/Tchkonia J Intern Med 2020; CALERIE-2\"}\n  ]\n}\n\u003c\/script\u003e\n\n\u003cdiv style=\"margin-top:28px;padding:14px 18px;background:#f5f5f5;border-radius:6px;font-size:13px;color:#444;line-height:1.65;\"\u003e\n\u003cstrong\u003eRegulatory and Methodological Framework:\u003c\/strong\u003e The Cellular Senescence Dual-Panel is conducted within an ISO 15189:2022-accredited medical laboratory with CAP external quality assurance programmes. p16INK4a and p21 quantification by digital droplet PCR (ddPCR) follows NIA\/NIH SenNet Consortium 2022 technical standards for senescent cell biomarker measurement in peripheral blood T-lymphocyte populations, with results normalised to ACTB (beta-actin) reference gene expression. SASP cytokine and protease quantification (IL-6, IL-8, TNF-α) complies with IFCC (International Federation of Clinical Chemistry) reference measurement procedures with WHO\/IFCC International Reference Preparations for cytokine calibration. GDF-15 measurement uses an electrochemiluminescence immunoassay (ECLIA, Roche Elecsys platform) traceable to WHO International Standard 14\/458. MMP-3 and PAI-1 measurements use validated multiplex immunoassay platforms (Luminex xMAP or equivalent) with inter-assay CV ≤15%. The Senescence Burden Index algorithm is based on the López-Otín et al. Hallmarks of Ageing framework (Cell 2013, updated Cell 2023) and calibrated against a normative age\/sex-matched database established from population reference studies including UK Biobank, EPIC-Norfolk, and CALERIE cohorts. Intervention guidance follows published evidence from the dasatinib + quercetin senolytic trials (Hickson et al. EBioMedicine 2019; Justice et al. EBioMedicine 2021), fisetin Phase I\/II data (Mayo Clinic SToMP series), and caloric restriction effects on senescence biomarkers (CALERIE-2, Racette et al. J Gerontol 2022). This assessment does not constitute medical diagnosis or treatment prescription. Results are interpreted by EMIS+ clinical scientists; intervention discussions involving prescription agents (dasatinib, rapamycin, JAK inhibitors) require consultation with a licensed MOH-registered physician in Singapore. Singapore HSA laboratory licensing regulations apply.\n\u003c\/div\u003e\n\n\u003cscript type=\"application\/ld+json\"\u003e\n{\n  \"@context\": \"https:\/\/schema.org\",\n  \"@type\": \"FAQPage\",\n  \"mainEntity\": [\n    {\n      \"@type\": \"Question\",\n      \"name\": \"What are the benefits of Cellular Senescence Dual-Panel for digestive health?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Cellular Senescence Dual-Panel by EMIS + supports digestive health and gut wellbeing. For individuals with digestive concerns such as IBS, bloating, or irregular bowel habits, targeted gut health supplementation may complement a balanced diet and lifestyle. Always consult a doctor or dietitian before starting supplements for digestive conditions.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Who should take Cellular Senescence Dual-Panel?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Cellular Senescence Dual-Panel may benefit adults seeking to support digestive health, those recovering from antibiotic use, individuals with irregular bowel habits, or those with conditions affecting gut microbiome balance. It is not a substitute for medical treatment. Consult your GP or gastroenterologist — available at SGH, NUH, Mount Elizabeth, and Raffles Hospital in Singapore — for personalised advice.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"How should I take Cellular Senescence Dual-Panel for best results?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Follow the dosage instructions on the Cellular Senescence Dual-Panel packaging or as directed by your healthcare provider. Consistency is key — most gut health supplements take 4–8 weeks of regular use to show measurable benefits. Store as directed on the label. Do not exceed the recommended daily dose.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Where can I buy Cellular Senescence Dual-Panel in Singapore?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Cellular Senescence Dual-Panel is available at EMIS+ (emis.asia) with fast Singapore island-wide delivery. We carry a curated range of clinically-informed digestive health supplements. Visit emis.asia or contact our team for product recommendations.\"\n      }\n    }\n  ]\n}\n\u003c\/script\u003e","brand":"EMIS +","offers":[{"title":"Default Title","offer_id":43526035636302,"sku":null,"price":649.0,"currency_code":"SGD","in_stock":true}],"url":"https:\/\/www.emis.asia\/products\/cellular-senescence-dual-panel","provider":"EMIS +","version":"1.0","type":"link"}